Shares in U.S. biotech company PTC Therapeutics more than doubled in premarket dealings on Friday after European regulators recommended a conditional class="mandelbrot_refrag">marketing authorization for Translarna, its drug for Duchenne muscular dystrophy.
_0">European Medicines Agency experts had adopted a negative opinion on the drug in January.
Conditional class="mandelbrot_refrag">marketing authorization is an early access mechanism for medicines that address an unmet medical need for patients suffering from life-threatening diseases, even if comprehensive clinical data are not yet available.
(Reporting by Ben Hirschler, Editing by Paul Sandle)